Oculis Holding AG has received FDA Special Protocol Assessment (SPA) approval for its Phase 3 PIONEER-1 trial of Privosegtor, a novel neuroprotective drug for optic neuritis (ON). This agreement confirms the trial design is suitable to support a future New Drug Application if results are positive. Privosegtor has shown promise in earlier trials and holds FDA Breakthrough Therapy and EMA PRIME designations, highlighting its potential to address a significant unmet need in neuro-ophthalmology. The PIONEER-1 trial will assess visual improvement and long-term safety in patients, including those with multiple sclerosis, aiming to offer the first neuroprotective therapy for ON.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
